We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+51.43%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
+$201M
Cap. Flow
-$41.4M
Cap. Flow %
-3.33%
Top 10 Hldgs %
81.83%
Holding
29
New
2
Increased
3
Reduced
11
Closed
3

Top Buys

Rank Stock Value
1
KYTX icon
Kyverna Therapeutics
KYTX
+$88.3M
2
DNTH icon
Dianthus Therapeutics
DNTH
+$65M
3
SLDB icon
Solid Biosciences
SLDB
+$8.46M
4
ANNX icon
Annexon
ANNX
+$3.33M
5
SVRA icon
Savara
SVRA
+$1.61M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$70M
2
RVMD icon
Revolution Medicines
RVMD
+$31.9M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$30.1M
4
NTRA icon
Natera
NTRA
+$25.1M
5
PHVS icon
Pharvaris
PHVS
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
1
NewAmsterdam Pharma
NAMS
$3.34B
$248M 19.91%
10,473,913
– –
NUVL
2
DELISTED
Nuvalent
NUVL
$203M 16.28%
2,697,267
-880,000
-25% -$70M
DNTH icon
3
Dianthus Therapeutics
DNTH
$6.25B
$89.8M 7.21%
+2,992,028
New +$65M
IRON icon
4
Disc Medicine
IRON
$3.01B
$82M 6.59%
1,317,213
-15,332
-1% -$994K
KYTX icon
5
Kyverna Therapeutics
KYTX
$480M
$78.6M 6.32%
+3,163,868
New +$88.3M
PHVS icon
6
Pharvaris
PHVS
$2.43B
$76.3M 6.14%
3,303,381
-600,938
-15% -$16M
SVRA icon
7
Savara
SVRA
$1.17B
$72.5M 5.83%
14,565,457
+332,706
+2% +$1.61M
ANNX icon
8
Annexon
ANNX
$883M
$62.4M 5.02%
8,703,268
+641,549
+8% +$3.33M
SLDB icon
9
Solid Biosciences
SLDB
$918M
$53.7M 4.32%
4,034,582
+904,160
+29% +$8.46M
MDGL icon
10
Madrigal Pharmaceuticals
MDGL
$11.9B
$52.6M 4.23%
196,995
-127,624
-39% -$30.1M
MRSN
11
DELISTED
Mersana Therapeutics
MRSN
$38.8M 3.12%
346,547
– –
CABA icon
12
Cabaletta Bio
CABA
$457M
$27.6M 2.22%
1,617,364
-382,636
-19% -$8.21M
XFOR icon
13
X4 Pharmaceuticals
XFOR
$421M
$23.5M 1.89%
563,859
– –
TNGX icon
14
Tango Therapeutics
TNGX
$4.51B
$23M 1.85%
2,892,663
– –
ARQT icon
15
Arcutis Biotherapeutics
ARQT
$3.26B
$19.9M 1.6%
2,011,687
-988,313
-33% -$7.38M
NRIX icon
16
Nurix Therapeutics
NRIX
$2.69B
$16.6M 1.34%
1,132,397
-690,486
-38% -$7.43M
SYRS
17
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$14.7M 1.18%
2,749,808
– –
MRNS
18
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$12.6M 1.01%
1,393,380
-37,678
-3% -$366K
AVIR icon
19
Atea Pharmaceuticals
AVIR
$402M
$10M 0.81%
2,485,638
– –
CCCC icon
20
C4 Therapeutics
CCCC
$400M
$9.33M 0.75%
1,142,210
-500,000
-30% -$3.88M
RPID icon
21
Rapid Micro Biosystems
RPID
$85.2M
$8.18M 0.66%
8,434,560
– –
IVVD icon
22
Invivyd
IVVD
$198M
$7.99M 0.64%
1,799,595
-137,612
-7% -$569K
NAUT icon
23
Nautilus Biotechnolgy
NAUT
$110M
$5.88M 0.47%
2,000,000
– –
ACRS icon
24
Aclaris Therapeutics
ACRS
$867M
$3.72M 0.3%
3,000,000
-500,000
-14% -$596K
XLO icon
25
Xilio Therapeutics
XLO
$60.5M
$3.03M 0.24%
200,387
– –
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q1 2024 Portfolio in Review

As of Q1 2024, Bain Capital Life Sciences Investors held 29 positions worth $1.24B, up 19% from $1.04B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $41.4M in Q1 2024, closing 3 positions and reducing 11 holdings. Its most notable exit was Revolution Medicines, an estimated $31.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, Bain Capital Life Sciences Investors opened a new position in Kyverna Therapeutics worth $78.6M.

  • Bain Capital Life Sciences Investors's largest Q1 2024 buy was Kyverna Therapeutics: 3,163,868 shares worth $78.6M.
  • Bain Capital Life Sciences Investors added most to Solid Biosciences in Q1 2024, an estimated $8.46M increase.
  • Bain Capital Life Sciences Investors's biggest Q1 2024 reduction was Nuvalent, cutting an estimated $70M.
  • Bain Capital Life Sciences Investors fully exited Revolution Medicines in Q1 2024, selling an estimated $31.9M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 82% of its $1.24B portfolio in Q1 2024.
  • Bain Capital Life Sciences Investors opened 2 new positions and closed 3 in Q1 2024.
  • Bain Capital Life Sciences Investors's portfolio value rose 19% quarter-over-quarter to $1.24B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2024, filed 15 May 2024.